Is GeneDx (WGS) Using Sponsored NPC Testing to Quietly Strengthen Its Data Advantage? [Yahoo! Finance]
Opko Health, Inc. (OPK)
Last opko health, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.opko.com
Company Research
Source: Yahoo! Finance
no-cost ExomeDx testing to eligible U.S. patients and contributing de-identified results to its GeneDx Infinity rare disease dataset. This collaboration highlights how sponsored genetic testing and data aggregation can help shorten diagnostic timelines in rare diseases and support more informed treatment decisions. We will now examine how this expanded access to ExomeDx testing for Niemann-Pick disease type C may influence GeneDx's investment narrative. AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. GeneDx Holdings Investment Narrative Recap To own GeneDx, you have to believe its rare disease focus, data assets, and payer relationships can support sustainable growth despite reimbursement and competition pressures. The NPC Sponsored Genetic Testing Program with Zevra looks directionally positive for deepening the I
Show less
Read more
Impact Snapshot
Event Time:
OPK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPK alerts
High impacting Opko Health, Inc. news events
Weekly update
A roundup of the hottest topics
OPK
News
- Craig-Hallum Reaffirms Buy on GeneDx (WGS) With $153 Price Target [Yahoo! Finance]Yahoo! Finance
- Previvor Edge Expands Platform to Deliver Personalized Clinical-Grade Cancer Risk Profiles and Interactive Prevention Plans [TheStreet.com]TheStreet.com
- Barrington Lowers PT on OPKO Health (OPK), Keeps a Buy [Yahoo! Finance]Yahoo! Finance
- “CNBC CURES: DEFYING RARE DISEASE” WITH BECKY QUICK TO PREMIERE ON THURSDAY, MARCH 19 AT 7PM ET [CNBC]CNBC
- GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
OPK
Earnings
- 2/26/26 - Beat
OPK
Analyst Actions
- 3/2/26 - Barrington Research
OPK
Sec Filings
- 3/20/26 - Form 4
- 3/20/26 - Form 4
- 3/20/26 - Form 3
- OPK's page on the SEC website